№ lp_1_2_23251
The document provides a review of clinical guidelines and cost estimates regarding the use of anti-epileptic drugs (AEDs) for epilepsy treatment in Australia, considering the cost to the Pharmaceutical Benefits Scheme (PBS) for allowing first-line use of levetiracetam (LEV) and lamotrigine (LTG) in the general population.
Year: 2025
Region / city: Australia
Subject: Clinical guidelines, Anti-epileptic drugs, Epilepsy treatment
Document type: Report
Organization: Pharmaceutical Benefits Advisory Committee (PBAC)
Author: Not specified
Target audience: Healthcare professionals, policymakers, pharmaceutical industry stakeholders
Period of validity: Not specified
Approval date: Not specified
Amendment date: April 2025
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.

Don’t have cryptocurrency yet?

You can still complete your purchase in a few minutes:
  1. Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
  2. In the app, tap Send.
  3. Select network, paste our wallet address.
  4. Send the exact amount shown above.
After sending, paste your TXID (transaction ID) and your email to receive the download link. Need help? Contact support and we’ll guide you step by step.